{"entity":{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","aka":[],"tldr":"Published report from the MINDACT trial registered as NCT00433589, in Annals of Oncology (2014), chosen as the most cited paper whose own text cites the registry id.","summary":"Background: To investigate the correlation of TargetPrint with local and central immunohistochemistry/fluorescence in situ hybridization assessment of estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) in the first 800 patients enrolled in the MINDACT trial.\n\nPatients and methods: Data from local (N = 800) and central (N = 626) assessments of receptor status were collected and compared with TargetPrint results.\n\nResults: For ER, the positive agreement (the percentage of central pathology positive assessments that were also TargetPrint/local laboratory positive) for TargetPrint in comparison to centralized assessment was 98% with a negative agreement (the percentage of central pathology negative assessments that were also TargetPrint/local laboratory negative) of 96%. For PgR, the positive agreement was 83% with a negative agreement of 92%. For HER2, the positive agreement was 75% with a negative agreement of 99%. Even though the local assessment showed higher positive agreement for PgR (89%) and higher positive agreement for HER2 (85%), the range of discordant local versus central assessments were as high as 6.7% for ER, 12.9% for PgR, and 4.3% for HER2.\n\nConclusion: TargetPrint and local assessment of ER, PgR, and HER2 show high concordance with central assessment in the first 800 MINDACT patients. However, there are concerns about the higher discordance rates for some local sites. TargetPrint can improve the reliability of hormone receptor and HER2 testing for those centers with a lower rate of concordance with the reference laboratory, with the limitation of a positive agreement of 75% for HER2. TargetPrint consequently has important implications for treatment decisions in clinical practice and is a reliable alternative to local assessment for ER.\n\nClinical trials number: NCT00433589.\n\nIndexed on Europe PMC as PubMed record 24667714 (DOI 10.1093/annonc/mdu026). Its abstract cites the registry id NCT00433589, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Ann Oncol 2014","url":"https://doi.org/10.1093/annonc/mdu026"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24667714/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/24667714"},{"label":"ClinicalTrials.gov NCT00433589","url":"https://clinicaltrials.gov/study/NCT00433589"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mindact"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu026","pmid":"24667714","authors":"Viale G, Slaets L, Bogaerts J, et al.","paperType":"rct","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT00433589 with the most citations, so it is the natural first reading for anyone following the MINDACT trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-mindact-ann-oncol-2014/","neighbours":{"trial":[{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}]}}